Ballentine Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $841K | Sell |
|
|||||
|
2025
Q2 | $758K | Sell |
|
|||||
|
2025
Q1 | $783K | Buy |
|
|||||
|
2024
Q4 | $580K | Buy |
|
|||||
|
2024
Q3 | $498K | Buy |
|
|||||
|
2024
Q2 | $465K | Sell |
|
|||||
|
2024
Q1 | $647K | Sell |
|
|||||
|
2023
Q4 | $695K | Sell |
|
|||||
|
2023
Q3 | $776K | Buy |
|
|||||
|
2023
Q2 | $710K | Buy |
|
|||||
|
2023
Q1 | $529K | Sell |
|
|||||
|
2022
Q4 | $525K | Buy |
|
|||||
|
2022
Q3 | $313K | Sell |
|
|||||
|
2022
Q2 | $915K | Sell |
|
|||||
|
2022
Q1 | $1.15M | Buy |
|
|||||
|
2021
Q4 | $929K | Buy |
|
|||||
|
2021
Q3 | $706K | Buy |
|
|||||
|
2021
Q2 | $600K | Buy |
|
|||||
|
2021
Q1 | $525K | Sell |
|
|||||
|
2020
Q4 | $639K | Buy |
|
|||||
|
2020
Q3 | $642K | Sell |
|
|||||
|
2020
Q2 | $714K | Buy |
|
|||||
|
2020
Q1 | $604K | Sell |
|
|||||
|
2019
Q4 | $881K | Buy |
|
|||||
|
2019
Q3 | $767K | Buy |
|
|||||
|
2019
Q2 | $716K | Sell |
|
|||||
|
2019
Q1 | $756K | Buy |
|
|||||
|
2018
Q4 | $639K | Sell |
|
|||||
|
2018
Q3 | $718K | Buy |
|
|||||
|
2018
Q2 | $710K | Buy |
|
|||||
|
2018
Q1 | $479K | Buy |
|
|||||
|
2017
Q4 | $386K | Buy |
|
|||||
|
2017
Q3 | $413K | Sell |
|
|||||
|
2017
Q2 | $451K | Buy |
|
|||||
|
2017
Q1 | $434K | Sell |
|
|||||
|
2016
Q4 | $398K | Buy |
|
|||||
|
2016
Q3 | $421K | Hold |
|
|||||
|
2016
Q2 | $423K | Sell |
|
|||||
|
2016
Q1 | $437K | Buy |
|
|||||
|
2015
Q4 | $369K | Sell |
|
|||||
|
2015
Q3 | $395K | Buy |
|
|||||
|
2015
Q2 | $368K | Sell |
|
|||||
|
2015
Q1 | $411K | Sell |
|
|||||
|
2014
Q4 | $383K | Buy |
|